Infectious disease
It has been one year since COVID-19 was declared a global pandemic. In that time, more than 118 million people have contracted the virus and 2,622,190 people, including 529,267 in the United States, have died as a result.
A machine learning model that screened 1,482 compounds potentially effective for treating coronavirus disease 2019 (COVID-19) has ranked Innovation Pharma’s COVID-19 candidate brilacidin in the top 3% of compounds predicted to be most effective against the novel coronavirus.
Bamlanivimab is a product born from a collaboration between Lilly and AbCellera, with Lilly reportedly developing the therapy in under three months following discovery by AbCellera.
In a list of the most innovative vaccine makers in 2021, Fast Company has outlined 10 biotech companies that continue to revolutionize the drug-discovery landscape.
In the wake of an increasingly accelerated COVID-19 vaccine rollout, the CDC has released new guidance statements that give fully vaccinated individuals more freedom to socialize and participate in pre-pandemic activities.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
There was a little bit of positive COVID-19 news to report today. Here’s a look.
The findings from the late-stage trial of Vyrologix have not been published, but CytoDyn said it is preparing a manuscript of the study data for submission.
The Russian government is attempting to cast a negative light on the COVID-19 vaccine developed by Pfizer and BioNTech, as well as other vaccines, in order to boost sales of its own vaccine, Sputnik V, the government charged.
Merck and Ridgeback Biotherapeutics announced preliminary results from Ridgeback’s Phase IIa trial of molnupiravir in COVID-19.
PRESS RELEASES